These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38688253)
21. Design, development, and in-vitro/in-vivo evaluation of docetaxel-loaded PEGylated solid lipid nanoparticles in prostate cancer therapy. Korake S; Bothiraja C; Pawar A Eur J Pharm Biopharm; 2023 Aug; 189():15-27. PubMed ID: 37270157 [TBL] [Abstract][Full Text] [Related]
22. The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. Runyan CE; Schnaper HW; Poncelet AC J Biol Chem; 2005 Mar; 280(9):8300-8. PubMed ID: 15613484 [TBL] [Abstract][Full Text] [Related]
23. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Zhang F; Lee J; Lu S; Pettaway CA; Dong Z Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637 [TBL] [Abstract][Full Text] [Related]
24. The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier. Vighi E; Montanari M; Ruozi B; Iannuccelli V; Leo E Drug Deliv; 2012 Jan; 19(1):1-10. PubMed ID: 22070724 [TBL] [Abstract][Full Text] [Related]
25. Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery. Yu W; Liu C; Ye J; Zou W; Zhang N; Xu W Nanotechnology; 2009 May; 20(21):215102. PubMed ID: 19423923 [TBL] [Abstract][Full Text] [Related]
26. DNA/Lipid complex incorporated with fibronectin to cell adhesion enhances transfection efficiency in prostate cancer cells and xenografts. Hattori Y; Maitani Y Biol Pharm Bull; 2007 Mar; 30(3):603-7. PubMed ID: 17329867 [TBL] [Abstract][Full Text] [Related]
27. Structural investigation and intracellular trafficking of a novel multicomposite cationic solid lipid nanoparticle platform as a pDNA carrier. Vighi E; Leot E; Montanari M; Mucci A; Hanuskova M; Iannuccelli V Ther Deliv; 2011 Nov; 2(11):1419-35. PubMed ID: 22826874 [TBL] [Abstract][Full Text] [Related]
28. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. Oner E; Kotmakci M; Baird AM; Gray SG; Debelec Butuner B; Bozkurt E; Kantarci AG; Finn SP J Nanobiotechnology; 2021 Mar; 19(1):71. PubMed ID: 33685469 [TBL] [Abstract][Full Text] [Related]
29. Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Park BJ; Park JI; Byun DS; Park JH; Chi SG Cancer Res; 2000 Jun; 60(11):3031-8. PubMed ID: 10850453 [TBL] [Abstract][Full Text] [Related]
30. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Choi SH; Jin SE; Lee MK; Lim SJ; Park JS; Kim BG; Ahn WS; Kim CK Eur J Pharm Biopharm; 2008 Mar; 68(3):545-54. PubMed ID: 17881199 [TBL] [Abstract][Full Text] [Related]
32. Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Dos Santos Rodrigues B; Lakkadwala S; Kanekiyo T; Singh J Int J Nanomedicine; 2019; 14():6497-6517. PubMed ID: 31616141 [TBL] [Abstract][Full Text] [Related]
33. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992 [TBL] [Abstract][Full Text] [Related]
34. Receptor-Mediated Targeting in Breast Cancer through Solid Lipid Nanoparticles and Its Mechanism. Malik Z; Parveen R; Abass S; Irfan Dar M; Husain SA; Ahmad S Curr Drug Metab; 2022; 23(10):800-817. PubMed ID: 35430962 [TBL] [Abstract][Full Text] [Related]
35. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines. Doktorovova S; Souto EB; Silva AM Pharm Dev Technol; 2018 Jan; 23(1):96-105. PubMed ID: 28949267 [TBL] [Abstract][Full Text] [Related]
36. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Delgado D; Gascón AR; Del Pozo-Rodríguez A; Echevarría E; Ruiz de Garibay AP; Rodríguez JM; Solinís MÁ Int J Pharm; 2012 Apr; 425(1-2):35-43. PubMed ID: 22226874 [TBL] [Abstract][Full Text] [Related]
37. Folate receptor mediated intracellular gene delivery using the charge changing solid lipid nanoparticles. Liu Z; Zhong Z; Peng G; Wang S; Du X; Yan D; Zhang Z; He Q; Liu J Drug Deliv; 2009 Aug; 16(6):341-7. PubMed ID: 19606948 [TBL] [Abstract][Full Text] [Related]